missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Obinutuzumab Recombinant Monoclonal Antibody
GREENER_CHOICE

Recombinant Monoclonal Antibody

477.00€ - 1204.00€

Spécification

Antigène Obinutuzumab Humanized
Concentration 1 mg/mL
Contenu et stockage -20°C, Avoid Freeze/Thaw Cycles
Applications ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Classification Recombinant Monoclonal
Consulter d'autres spécifications

Produits 2
Code produit Marque Quantité Prix Quantité et disponibilité  
Code produit Marque Quantité Prix Quantité et disponibilité  
30284033
GREENER_CHOICE
Afficher les documents
Invitrogen™
MA558259
100 μg
477.00€
100µg
Voir les produits de remplacement
Économisez jusqu'à 
»
Veuillez vous pour pouvoir commander cet article. Besoin d'un compte web? Créer le vôtre dès maintenant!
30283043
Afficher les documents
Invitrogen™
MA558260
1 mg
1204.00€
1mg
Voir les produits de remplacement
Économisez jusqu'à 
»
Veuillez vous pour pouvoir commander cet article. Besoin d'un compte web? Créer le vôtre dès maintenant!
Description

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Spécification

Spécification

Obinutuzumab Humanized
-20°C, Avoid Freeze/Thaw Cycles
Recombinant Monoclonal
Lyophilized
IgG1
Human
afutuzumab; Gazyva; Gazyvaro; RG7159; RO5072759
Antibody
1 mg/mL
ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Unconjugated
Human
RUO
25mM Histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Primary
Protein A
Videos
SDS
Documents

Documents

Certificates
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.